Large gap with delayed quotes
|
Last quote
07/03/2025
-
02:00:00
|
Bid
07/03/2025 -
14:30:31
|
Bid Volume |
Ask
07/03/2025 -
14:30:31
|
Ask Volume |
|---|---|---|---|---|
|
2.56
+0.31
(
+13.78% )
|
2.50
|
800 |
2.81
|
100 |
Analysis date: 01.07.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 16.05.2025.
Interest
Weak
Weak
Two stars since 01.07.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 01.07.2025 at a price of 2.25.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The forty day technical trend is positive since 20.05.2025.
4wk Rel Perf
22.70%
22.70%
The four-week dividend-adjusted overperformance versus SP500 is 22.70%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 2.29%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 6.50%.
Mkt Cap in $bn
0.18
0.18
With a market capitalization <$2bn, EDITAS MEDICINE is considered a small-cap stock.
G/PE Ratio
5.21
5.21
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
-1.97
-1.97
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
10.27%
10.27%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
11
11
Over the last seven weeks, an average of 11 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
199
199
For 1% of index variation, the stock varies on average by 1.99%.
Correlation
0.42
0.42
42.20% of stock movements are explained by index variations.
Value at Risk
2.03
2.03
The value at risk is estimated at USD 2.03. The risk is therefore 90.10%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.12.2018
21.12.2018